A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)
Open Access
- 30 September 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (58) , 98426-98454
Abstract
A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A) A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)Keywords
This publication has 134 references indexed in Scilit:
- The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivoEuropean Journal of Cancer, 2013
- Balancing the fat: lipid droplets and human diseaseEMBO Molecular Medicine, 2013
- Sen1p Contributes to Genomic Integrity by Regulating Expression of Ribonucleotide Reductase 1 (RNR1) in Saccharomyces cerevisiaePLOS ONE, 2013
- Yeast and cancer cells – common principles in lipid metabolismBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013
- Contribution of histone N‐terminal tails to the structure and stability of nucleosomesFEBS Open Bio, 2013
- Increased unsaturation of lipids in cytoplasmic lipid droplets in DAOY cancer cells in response to cisplatin treatmentMetabolomics, 2012
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatmentDrug Resistance Updates, 2008
- Chromatin Modifications and Their FunctionCell, 2007
- The Hallmarks of CancerCell, 2000